

# The food contaminant, deoxynivalenol, modulates the Thelper/Treg balance and increases inflammatory bowel diseases

Delphine Payros, Sandrine Ménard, Joelle Laffitte, Manon Neves, Marie Tremblay-Franco, Su Luo, Edwin Fouche, Selma P Snini, Vassilia Theodorou, Philippe Pinton, et al.

#### ▶ To cite this version:

Delphine Payros, Sandrine Ménard, Joelle Laffitte, Manon Neves, Marie Tremblay-Franco, et al.. The food contaminant, deoxynivalenol, modulates the Thelper/Treg balance and increases inflammatory bowel diseases. Archives of Toxicology, 2020, 94 (9), pp.3173-3184. 10.1007/s00204-020-02817-z. hal-04777173

### HAL Id: hal-04777173 https://hal.science/hal-04777173v1

Submitted on 30 Jan 2025

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

## The food contaminant, deoxynivalenol, modulates the Thelper/Treg balance and increases inflammatory bowel diseases

Delphine Payros<sup>1</sup> · Sandrine Ménard<sup>1</sup> · Joelle Laffitte<sup>1</sup> · Manon Neves<sup>1</sup> · Marie Tremblay-Franco<sup>1</sup> · Su Luo<sup>1</sup> · Edwin Fouche<sup>1</sup> · Selma P. Snini<sup>1</sup> · Vassilia Theodorou<sup>1</sup> · Philippe Pinton<sup>1</sup> · Isabelle P. Oswald<sup>1</sup>

<sup>1</sup>Toxalim (Research Center in Food Toxicology), INRAE, ENVT, INP- PURPAN, UMR 1331, UPS, Université de Toulouse, 180 Chemin de Tournefeuille, BP93173, cedex 03, F-31027 Toulouse, France

Corresponding author: Isabelle P. Oswald isabelle.oswald@inrae.fr

#### **Abstract**

The incidence of inflammatory bowel diseases (IBD) is increasing in both Western and developing countries. IBD are multifactorial disorders involving complex interactions between genetic, immune, and environmental factors such as exposure to food contaminants. Deoxynivalenol (DON) is the most prevalent mycotoxin that contaminates staple food and induces intestinal breakdown and inflammatory response. To delineate the role of DON oral exposure in IBD, we used a Dextran sulfate sodium (DSS) colitis model in rats fed with a DON-contaminated diet or a control diet for 4 weeks. Colitis was induced in the 4th week by increasing concentrations of DSS in the drinking water (0, 2, 3 or 5%). DON exacerbated body weight loss and accelerated the appearance of symptoms in animals treated with DSS. DON increased morphological damage, proinflammatory markers (myeloperoxidase, CXCL-1 and IL-1 $\beta$ ) and immune cell responses. In *lamina propria* of the rat with colitis, DON increased adaptive and innate immune responses after anti-CD3/28 or LPS stimulation, respectively. In the spleen, DON increased IFN $\gamma$  secretion and reduced Treg populations. Interestingly, De-epoxy-DON (DOM-1) a detoxified form of DON did not have any consequences on colitis. These results suggest that DON is a risk factor in the onset of IBD.

**Keywords** Mycotoxin · De-epoxy-DON: DOM-1 · Intestine · Spleen · Colitis · Immune response

The online version of this article (https://doi.org/10.1007/s00204-020-02817-z) contains supplementary material, which is available to authorized users.

#### Introduction

The incidence of inflammatory bowel diseases (IBD, Crohn's disease; CD and ulcerative colitis, UC) has risen in recent decades in both Western and developing countries (Weimers and Munkholm 2018). IBDs are characterized by chronic intestinal and systemic inflammation associ- ated with the disruption of the intestinal barrier and micro- biota dysbiosis in favor of enterobacteria (Chassaing and Darfeuille-Michaud 2011; Zhang and Li 2014). Genetic and environmental factors play a major role in the develop- ment of these multifactorial diseases; among environmental factors, changes in diet, antibiotic use, microbial exposure or exposure to food contaminants have been identified as risk factors for the development of IBD (Ananthakrishnan et al. 2017; Chassaing et al. 2015).

Trichothecene mycotoxins are fungal secondary metabo- lites that can contaminate a wide variety of dietary material consumed by humans and animals. Among these mycotox- ins, deoxynivalenol (DON), produced by *Fusarium* species is commonly detected in cereals and associated products (flour, pasta or bran). DON is among the most prevalent contaminants in cereal-based food, suggesting regular human exposure (Knutsen et al., 2017; Wang et al., 2014). Analyses of urine samples indicated that 98% of adults in the UK had been exposed to DON, while 30 to 80% in France and the Netherland respectively exceeded the tolerable daily intake of this mycotoxin (Pieters et al. 2002; Turner et al. 2008; Vin et al. 2020).

Previous studies by our laboratories and others demon- strated that DON disrupts the intestinal barrier functions (Akbari et al. 2014; Pinton et al 2012; Pinton and Oswald 2014), induces intestinal inflammatory responses (Pestka 2010; Cano et al. 2013; Alassane-Kpembi et al. 2017) and

exacerbates the genotoxic effect of intestinal microbiota on epithelial cells (Payros et al., 2017). Recently, Vignal et al. observed that chronic ingestion of DON impairs intestinal homeostasis by altering the immune response in mesenteric lymph nodes and gut microbiota composition (Vignal et al. 2018). All these data suggest that DON is a risk factor for the development and/or the exacerbation of IBD (Maresca and Fantini 2010), but this has never been demonstrated. At the molecular level, DON interacts with the peptidyl trans- ferase region of the 60S ribosomal subunit, inducing "ribot- oxic stress" that results in the activation of mitogen-activated protein kinases (MAPKs) and their downstream pathways (Lucioli et al. 2013; Pierron et al. 2016).

Using a rat model of colitis induced by increasing doses of Dextran sulfate sodium (DSS), we investigated the role of exposure to DON in the increased incidence of IBD.

#### Material and methods

#### **Chemicals**

Purified DON was purchased from Sigma (St Quentin Fal- lavier, France). De-epoxy-DON (DOM-1) a detoxified form, was obtained by transforming crystalline DON (Romer Labs, Tulln, Austria) as previously described (Pierron et al. 2016). DON and DOM-1 were included in the animals' diet premix (Payros et al. 2017). Control and mycotoxin-contaminated diets were manufactured at the INRAe UPAE (Jouy en Josas, France) and formulated according to the requirements estab- lished for rats (Supplementary Material Table S1). Labo- cea (Plouflagran France) checked DON (8.18 mg/kg) and DOM-1 (8.01 mg/kg) concentrations in the final diet by HPLC–MS/MS.

#### Animal model of DSS-induced colitis

Male Wistar rats (140–170 g body weight, 4 weeks old, Jan- vier, France) were maintained in the Toxalim animal facility (INRAE, UMR 1331, Toulouse), with free access to food and water throughout the study. The experiments were car- ried out in accordance with the European Guidelines for the care and use of animals for Scientific Purposes and validated by Toxcomethique Ethics Committee and the French Min- istry of National Education Higher Education and Research (APAFIS#4832–2,016,040,716,495,113). After 5 days of

acclimatization, the animals received the control, DON or DOM-1 contaminated diet (8 mg.kg<sup>-1</sup>) for 4 weeks. In the last week, colitis was induced in some animals by adding DSS (0, 2, 3 or 5%) to the drinking water (Supplementary Material Fig. 1) for 7 days and the rats were then euthanized by cervical dislocation and exsanguination. A persistently hunched posture and labored respiration, a weight loss of more than 20% were considered as end-points at which the animals were euthanized.

#### Clinical scoring of DSS-induced colitis

Bodyweight, stool consistency and bleeding were monitored daily. Clinical scoring (0–4) was based on the evaluation of the last two parameters (Schultz et al. 2004) (Supplementary Material Table S2).

#### Microscopic scoring analysis

The colon was fixed in 10% buffered formalin for 24 h, dehydrated and embedded in paraffin using standard his- tological procedures. Sections (5 μm) were stained with H&E (Hemalun and Eosin). For the analysis of microscopic scoring after DSS-induced colitis, colonic inflammation and damage were graded semi-quantitatively blindly by one or two of the authors according to the method of Tamaki et al. (Tamaki et al. 2006). Each of three histological features (severity of inflammation, the extent of inflammation and damage to the epithelium) was scored from 0 to 4. Tissue extent was also taken into account (0– > 75%). The histologi- cal score was the sum of these parameters (Supplementary Material Table S3).

#### Myeloperoxidase (MPO) activity

Myeloperoxidase (MPO) is a granule-associated enzyme present in neutrophils and other cells of myeloid origin and is widely used as a marker of intestinal inflammation. Distal segments of colon (1 cm) were sectioned transversely and stored at -80 °C until assayed for measurement of MPO activity. MPO is expressed in units (U) per gram of colonic protein, where 1 U corresponds to the activity required to degrade 1  $\mu$ mol of hydrogen peroxide in 1 min at room tem- perature.

Protein concentrations were determined using the BCA Assay Uptima kit (Interchim, Montluçon, France).

#### **Cytokine measurements**

For tissue samples, distal segments of colon (0.5 cm pieces) were stored at -80 °C. Tissue proteins were extracted with RIPA buffer (1% Igepal, 0.5% deoxycholic acid and 0.1% sodium dodecyl sulfate in Tris-buffered saline 1X; pH = 7.4) with protease inhibitor cocktail (Roche diagnostic, France). Protein concentrations were determined as above. Clear lysates of colon or cell culture supernatant (see below) were processed for ELISA using commercial ELISA kits (Duoset R&D Systems, Lille, France) for Interleukin-1 $\beta$  (IL- 1 $\beta$ ), IFN $\gamma$ , IL-17, IL-10, TNF $\alpha$  and the chemokine CXCL-1 (CINC-1, rat Interleukin-8) according to the manufacturer's instructions. Data are expressed as picograms of cytokine per milliliter of cell culture medium or per milligram of tis- sue protein.

#### Cell isolation and flow cytometry analysis

Ileal small intestines were washed with cold PBS, cut into 0.5 cm pieces, incubated in 3 mM EDTA (Sigma) and digested in Dulbecco Modified Eagle Medium (DMEM) supplemented with 20% fetal calf serum and 100 U/mL of collagenase (Sigma) for 40 min at 37 °C before filtration and purification by centrifugation using a gradi- ent of 40–80% Percoll. Spleen cells were collected in a 70  $\mu$ m strainer, washed and separated from red blood cells with ammonium–chloride–potassium (ACK) lysis buffer. Isolated cells from ileal *lamina propria* (iLP) and spleen were seeded on 24-well plates (1.10 $^6$  cells per well) previ- ously coated or not with 5  $\mu$ g/ml hamster anti-rat CD3 and hamster anti-rat CD28 (G4.18 and JJ319, ebioscience) in Cerrotini medium (DMEM supplemented with 20% SVF, 36 mg/l asparagine, 116 mg/l arginine, 10 mg/l folic acid, 1 g/l 4-[2-hydroxyethyl]-1-piperazineethanesulfonic acid,

0.05 mmol/l β-mercaptoethanol, 100 U/ml penicillin, 100 kg/ml streptomycin and 1 μg/ml fungizone). After 72 h of stimulation, culture supernatants were collected and stored at -80 °C until cytokine assays were performed. In paral-lel, lipopolysaccharide (LPS) stimulation (100 ng/ml) was performed for 16 h before the supernatants were collected to assess innate immune response. To assess dendritic cell (DC) maturation, cells were stimulated with 40 µg/ml Pol- yinosinicpolycytidylic acid sodium salt(poly I:C, (Sigma) and 20 µg/ml LPS (Sigma) overnight before cell phenotype analysis by flow cytometry. Antibodies were incubated at 4 °C for 30 min. Antibodies directed against CD103 (OX-62, Biolegend, San Diego, USA) and CD11b/c (OX-42, BD Pharmingen, Grenoble, France) were used to determine DC phenotype. CD4 (W3/25, Biolegend) and CD25 (OX-39, Biolegend) were used to identify helper T cells. Intracellular staining of FoxP3 (JFK-16S, eBioscience) in CD4<sup>+</sup> T lym- phocytes was performed using a Cytofix/Cytoperm Kit Plus (BD Bioscience, CA, USA) to detect regulatory T cells. To quantify the Th17 lymphocytes, cells were stained with anti- TCRαβ antibody (clone R73, BD Pharmingen) and intra- cellular cytokine staining was performed with anti-IL-17F (8F5.1A9, Biolegend) antibodies. Cells were stimulated with a cocktail of phorbol 12-myristate 13-acetate (PMA, 15 nM, Sigma) and ionomycin (1 μg/mL Sigma) for 5 h at 37 °C. Brefeldin A (10 μg/mL, Sigma) was added after the first hour of incubation. Cells were harvested, washed and stained with anti-IL-17F antibodies for 30 min at 4 °C. Flow cytometry data were collected on MACSQuant Analyzer (Miltenyi Bio- tec, Paris, France) and analyzed using VenturiOne® (Applied Cytometry, Dinnington, UK) software.

#### Statistical analysis

Statistical differences between the experimental groups were evaluated by two-way analysis of variance, followed by a Bonferroni post-test (which allows comparison of all pairs of groups). All tests were performed with GraphPad Prism Software (Inc, San Diego, CA). All data are pre- sented as means  $\pm$  the standard errors of the mean (SEM). A p value of < 0.05 was considered significant.

To evaluate the differences for clinical score and body weight gain, a linear mixed model for repeated measures was fitted. Diet, Time and interaction Time x Effect were set to fixed effects. The time was considered as a repeated measure within the rat, and the rat was assumed as a ran- dom effect. The Shapiro–Wilk test was used to assess nor- mality of model's residuals. Differences of Least Squares Means were applied to test pairwise comparisons. Pack- ages lme4 and lmerTest of the R project (https://www.r- project.org/) were used to perform theses analyses.

#### Results

## DON exposure accelerates the onset and exacerbates DSS-induced colitis in adult rats

To assess the deleterious effect of DON on colitis, a DSS- induced colitis model was used with rats exposed or not to a DON contaminated diet (8 mg.kg<sup>-1</sup>). As already described (Egger et al. 2000) rodents exposed to DSS in drinking water (2, 3 or 5% DSS) exhibit clinical features—of acute colitis including diarrhea and rectal bleeding after 7 days in contrast to DSS untreated rats fed a control or DON-contaminated diet (Fig. 1a). Combined exposure to DON and DSS at all doses tested, significantly accelerated the onset of symptoms (occurrence of diarrhea and blood—in feces) and aggravated clinical scores (Fig. 1a, Supple- mentary Table S4). The exacerbation of the clinical symp- toms in presence of DON was associated with a significant decrease in body weight gain in animals that received 5% DSS (Fig. 1b), as well as a significant decrease in colon length (Supplementary Figure S2). DSS-induced colitis also led to fecal microbiota dysbiosis in favor of *Entero- bacteriaceae* (Supplementary Figure S3).

Taken together, these results indicate that exposure to DON accelerates the appearance of clinical symptoms in animals treated with DSS and aggravates DSS-induced colitis at all doses of DSS tested but with a stronger effect at 5% DSS.




Fig. 1 Effect of exposure to DON on the development of DSS- induced colitis in rats with increased doses of DSS. a Colitis severity in response to 0%, 2%, 3% or 5% DSS. b Body weight gain (% of initial body weight before DSS treatment). Results are expressed as mean  $\pm$  SEM (n = 9-15). One-way ANOVA with Bonferroni's multiple comparison test was used to compare the effect of DON expo- sure within a group treated with DSS (0, 2, 3 or 5%). Linear mixed model for repeated measures was performed to analyze the effect of the diet (D), the time (T) and the interaction (DxT); \* $p \le 0.05$ , \*\* $p \le 0.01$ , \*\*\* $p \le 0.001$ 

## Exposure to DON-contaminated diet exacerbates morphological damage and inflammatory response in the colon of rats with DSS-induced colitis

Morphological damage in the colon was evaluated at the end of the experiment (4 weeks of exposure to DON plus exposure to DSS in the last week of DON exposure). Treatment with 2%, 3% or 5% DSS led to the progressive appearance of multifocal inflammatory cell infiltration, edema, epithe- lial cell and crypt loss and colonic inflammation (Fig. 2a, b). In animals treated with 3% or 5% DSS, exposure to the DON-contaminated diet further increased the histological scores (Fig. 2a, b). In animals treated with the highest dose of DSS (5%), the colon displayed loss of crypts and loss of epithelium cell surface. These features, especially loss of crypts, necrotic and apoptotic debris and loss of epithe- lium cell surface were also observed in animals fed DON- contaminated diet and exposed to lower doses of DSS (2% and 3%) (Fig. 2b).

The inflammatory status of the colon was then assessed. In rats treated with 5% DSS, exposure to the DON-con-taminated diet induced a stronger inflammatory response as evidenced by the increased levels of myeloperoxidase (MPO) (Fig. 2c), chemokine ligand 1 (CXCL-1, a homolog of Interleukin-8) (Fig. 2d) and IL-1 $\beta$  (Fig. 2e). Increased levels of CXCL-1 and IL1- $\beta$  were also observed in animals treated with 3% DSS due to the exacerbating effect of DON (Fig. 2d, e).

These results demonstrate that DON worsens colitis induced by DSS through the exacerbation of morphologi- cal damage and increased production of pro-inflammatory markers.

#### DON but not DOM-1, a detoxified form of DON, exacerbates colitis induced with 5% DSS

To investigate if the exacerbation of DSS induced colitis was specific to DON, the DOM-1, a detoxified form of DON (Pierron et al. 2018; Bracarense et al. 2020), was used. Expo- sure to DOM-1 did not increase the severity of the symptoms (Fig. 3a, b). In 5% DSS treated rats, exposure to DON but not to DOM-1 reduced colon length (Supplementary Fig. 4a) and

increased populations of *Enterobacteriaceae* in feces (Supplementary Fig. 4b). Similarly, in animals exposed to DSS, the exacerbation of intestinal damages (Fig. 3c, d) and the increase in MPO in colonic tissue (Fig. 3e) were observed in animals fed DON contaminated diets but not in animals fed DOM-1contaminated diets.




Fig. 2 Effect of exposure to DON on morphological damage in the colon of animals treated with increased doses of DSS. a Histological scores. b Representative distal colon sections stained with H&E.

<sup>\*</sup> loss of crypt, # necrotic and apoptotic debris, filled with square immune cell infiltration, (arrow) loss of epithelial cell surface. Images in each row are at the same magnification (×10). Bars = 100  $\mu$ m. c MPO activity. d Chemokine production CXCL-1 (IL-8) and cytokine production IL-1 $\beta$  (e). Results are expressed as mean  $\pm$  SEM (n = 9-15). One-way ANOVA with Kruskal–Wallis test, Dunn's mul- tiple comparison test were used to compare the effect of DSS (black stars) or within a group treated with DSS (0, 2, 3 or 5%) the effect of DON exposure (red stars); \* $p \le 0.05$ , \*\* $p \le 0.01$ , \*\*\* $p \le 0.001$ 

## DON but not DOM-1 exposure induced an intestinal pro-inflammatory response in 5% DSS-induced colitis in rats

To further understand the mechanism by which exposure to DON exacerbates 5% DSS-induced colitis, local and sys-temic immune responses were investigated. Immune cells population and functionality were studied in the ileal *lamina propria* of animals exposed or not to the highest dose of DSS (5%) and fed control, or DON- or DOM-1-contami- nated diets.

As already reported (Leppkes et al. 2009) colitis increased the percentage of Th17 cells (Fig. 4a, b  $TCR\alpha\beta^{+}$  IL- 17<sup>+</sup>), and the percentage of helper T cells (Th) (Fig. 4c, CD4<sup>+</sup>CD25<sup>+</sup> cells) without influencing the percentage of regulatory T cells (Treg) (CD4<sup>+</sup>CD25<sup>+</sup> FoxP3<sup>+</sup> cells) (Fig. 4d). DSS treatment increased the percentage of colito-genic dendritic cells (CD103 CD11b/c<sup>+</sup>) but had no effect on the percentage of tolerogenic dendritic cells (CD103 CD11b/c (Fig. 4f, g). When assessing the functionality of the cells, anti-CD3/28 stimulation-induced IL-17, IFNy and IL-10 secretion IL-17 (Fig. 4h) and IL10 (Fig. 4j) secretions were significantly higher in cells isolated from DSS- treated rats and stimulated with anti-CD3/28 whereas IFNy (Fig. 4i) secretion was not affected. By contrast, in non- stimulated cells, the secretion of pro- and anti-inflammatory cytokines was not affected by exposure to either DSS or DON (Fig. 4h-j). When DSS-treated rats were fed the DON-contaminated diet, higher IL-17 secretion in response to anti-CD3/28 stimulation was observed with no change in Th17 populations (Fig. 4a, b, h). Combined exposure to DON and DSS also reduced the Treg/Th ratio (Fig. 4a, e) associated with a drastic increase in the percentage of helper T cells (Fig. 4c) and a decrease in IL-10 secretion in response to anti-CD3/28 (Fig. 4J). The combined exposure significantly increased the frequency of pro-inflammatory dendritic cells (CD103<sup>-</sup>CD11b/c<sup>+</sup>) but had no effect on the percentage of tolerogenic dendritic cells (CD103<sup>+</sup> CD11b/c<sup>-</sup>) (Fig. 4f, g). Upon LPS stimulation, the secretion of IL-1β (Fig. 4l) increased significantly in rats with colitis and fed the DON- contaminated diet. By contrast, the frequency of activated T cells (CD4<sup>+</sup> CD44<sup>high</sup> CD62L<sup>low</sup> positive cells) was not affected (Supplementary Figure S5A).

These cellular inflammatory effects were not observed in DSS-treated rats fed the DOM-contaminated diet. However, in

DSS-treated rats, exposure to DOM-1-contaminated feed significantly increased the percentage of tolerogenic DC (CD103<sup>+</sup> CD11b/c<sup>-</sup>) (Fig. 4g) and reduced the secretion of TNFα after LPS stimulation (Fig. 4k).

Taken together, these results indicate that in the *lamina propria* of rats treated with 5%-DSS, additional exposure to DON- but not DOM-1-contaminated feed -exacerbates the pro-inflammatory T cell and dendritic cells immune responses and reduces the anti-inflammatory response.


## Exposure to DON but not to DOM-1 induced systemic pro-inflammatory response in 5% DSS-induced colitis in rats

To analyze if DON exposure had any consequences for the systemic immune response, the response of spleen cells was investigated. DSS treatment significantly increased the frequency of Th17 cells without modifying the frequency of Treg and T helper or affecting the Treg/Thelper ratio (Fig. 5a–d). No effect was observed on the frequency of colitogenic DC whereas an increase in tolerogenic DC was observed in animals suffering from colitis (Supplementary Fig. 6a and 6b). In response to anti-CD3/28, the secretion of IL-17 (Fig. 5e) was significantly higher in the DSS-treated group compared to the control group, whereas no effect was observed on the secretion of IFN $\gamma$  and IL-10 (Fig. 5f, g). Upon LPS stimulation, the secretion of IL-1 $\beta$  increased in rats suffering from colitis compared to control animals, whereas no effect was observed on TNF $\alpha$  secretion (Sup-plementary Fig. 6C and 6D).

As observed in the intestine, when DSS-treated rats were fed with the DON-contaminated diet, a tendency to an increased number of Th17 (Fig. 5a) cells as well as an exacerbation of IL-17 (Fig. 5e) and IFN $\gamma$  (Fig. 5f) secretion in response to anti-CD3/28 were observed. DON reduced the Treg/T helper ratio (Fig. 5d) in DSS treated rats, increased the number of T helper cells (Fig. 5c) and reduced the per- centage of regulatory T cells (Fig. 5b) without modify- ing the secretion of IL-10 (Fig. 5g). In the spleen of DSS treated rats, DC populations were not affected (Supplementary Fig. 6a and 6b) and DON exposure did not modify the secretion of IL-1 $\beta$  but increased the secretion of TNF $\alpha$  in response to LPS stimulation (Supplementary Fig. 6c and 6d). No modification of activated T cells was observed (Sup- plementary Fig.5b).

These systemic inflammatory effects were not observed in DSS-treated rats fed the DOM-contaminated diet. However, in DSS-treated rats, in response to anti-CD3/28, exposure to the DOM-contaminated feed significantly increased the secretion of IFN $\gamma$  (Fig. 5f) and IL1-0 (Fig. 5g) in spleno- cytes whereas the frequency of Th17 cells in the Treg/Th ratio remained unchanged (Fig. 5a, d).

In summary, these data demonstrate that in rat with coli- tis, exposure to DON contaminated feed modulates the systemic immune response with an increase in IL-17 and IFN $\gamma$  immune response in the spleen.



**Fig. 3** Effect of DON and DOM-1 exposure on the development of colitis and morphological attempts in animals treated with 5% of DSS. **a** Disease severity. **b** Body weight gain (% of initial body weight before DSS treatment). **c** Histological score. **d** Representative distal colon sections stained with H&E. Images in each row are at the same magnification: ×2 (above) and ×10 (below). Bars = 500 μm(above) or 100 μm (below). **e** MPO activity. Results are expressed as mean ± SEM (n = 9 - 15). One-way ANOVA with Kruskal–Wallis test, Dunn's multiple comparison test was used to compare two groups. In panels A and B, linear mixed model for repeated measures was per- formed to analyze the effect of the diet (D), the time (T) and the inter- action (DxT); \*\*  $p \le 0.05$ , \*\*\*.  $p \le 0.01$ , \*\*\*.  $p \le 0.001$ 

#### **Discussion**

IBD are multifactorial diseases associated with impaired intestinal barrier functions and dysbiosis of intestinal microbiota (Zhang and Li 2014). The prevalence of IBD has rapidly increased in recent decades especially in North- ern Europe and Northern America, and currently affects five million patients worldwide (Weimers and Munkholm 2018). Besides genetic predisposition, a role for environmental fac- tors has been suggested (Kaplan and Ng 2017). In this study, the effect of a mycotoxin, DON, was investigated to deter- mine whether it is a risk factor for IBD.

DON was incorporated in the diet to mimic consumer exposure, which occurs mainly through food intake. Ani-mals were exposed to a very low concentration of the food contaminant DON in their diet. Indeed, the concentration of 8.2 mg DON/kg feed is within the no observed adverse effect levels (NOAELs) determined in different studies in rats. Arnold et al. (1986) determined a NOAEL of 5 mg /kg feed in rats exposed to DON for 9 weeks (Arnold et al. 1986), whereas Sprando et al. (2005) and Morrissey et al. (1985) determined a NOAEL of 20 mg/kg feed in rat exposed to this toxin for four and 12 weeks, respectively (Morrissey et al. 1985; Sprando et al. 2005).


In this study, a rat model of DSS-induced colitis was used to evaluate the potential impact of exposure to low doses of DON on the onset and the exacerbation of IBD. DSS was added to drinking water for a short period and induced reproducible colitis (Ni et al. 1996; Egger et al. 2000). Recent studies investigated the deleterious effect of food additives and food contaminants on the development of IBD. Chas- saing et al. showed that food additives such as the synthetic emulsifiers carboxymethyl cellulose and polysorbate 80 are involved in the development of IBD through microbiota dysbiosis and intestinal inflammation (Chassaing et al. 2017). Similarly, Breton et al. demonstrated that short-term expo- sure to cadmium (Cd, 5 µg.kg<sup>-1</sup>) accentuated the symptoms of colitis in a DSS mice model (Breton et al. 2016). In the present study, we demonstrated that ingestion of DON-con- taminated diet exacerbated the onset and the symptoms of colitis in rats treated with DSS. This effect was specific to DON, as a detoxified form of DON, DOM-1, had no effect. Among food contaminants, the mycotoxin DON is pre- sent in large amounts in cereals especially in wheat and maize (Knutsen et al. 2017). The worldwide incidence of DON contamination in food is high because of increased use of no till farming, non-optimal crop rotation and inad- equate fungicide treatments (Larsen et al. 2004; Knutsen et al. 2017). Interestingly, this important exposure to DON coincides with a higher incidence of IBD, we thus hypoth- esize that DON plays a deleterious role in IBD onset and/ or exacerbation.

There is overwhelming evidence that when present at moderate to high doses, DON, induces a systemic and intestinal inflammatory response in healthy animals (Pestka 2010; Payros et al. 2016; Robert et al. 2017). In the present study, we observed that a very low dose of DON, below the one inducing the secretion of mediators such as MPO, CXCL-1 and IL-1β, exacerbated intestinal inflammation in colitis induced with 3% and 5% DSS in rats. In clinical studies, IL-1β levels have been reported to correlate posi- tively with IBD severity (Reinecker et al. 1993; Opipari and Franchi 2015) and to act in concert with other pro-inflamma- tory mediators to induce Th17 and Th1 immune responses, key mediators of colitis (Ludwiczek et al. 2004; Raza et al. 2012). In animals fed a DON-contaminated diet with DSS- induced colitis, the elevated IL-1β secretion was associated with an increase in the population of Th17 and an increase in IL-17 secretion. Patients with ulcerative colitis present a default in the CD103<sup>+</sup> DC function with impaired ability to generate Treg and exhibit a colitogenic function inducing Th1/Th17 responses (Matsuno et al. 2017). We observed that DON increased proinflammatory DC CD103<sup>-</sup> CD11b/c<sup>+</sup> in lamina propria of rats where colitis was induced with 5% DSS. Taken together, our results strengthen the hypothesis of a role for IL-1 $\beta$  and IL-17 in DON colitis. Few studies have investigated the effects of DSS induced colitis on systemic immune responses (Abron et al. 2018). The present experiment demonstrated high IL-17 secretion as well as a decrease in the Treg/Thelper ratio in rats treated with DSS and exposed to DON. Moreover, DOM-1 has no effect on systemic immune population cells but increased the secre- tion of IFN and IL-10 confirming that DOM-1 has some immune-modulatory properties in the spleen as evidence by increased the number of proliferating cells in this organ and specific antibody response (Pierron et al. 2018).

As mentioned above, IBD are multifactorial diseases.

Among the different factors involved, intestinal hyper- permeability also plays a role in the development of colitis (Wyatt et al., 1993). The disruption of the barrier functions observed in DON treated cells, explants and animals (Lucioli et al. 2013; García et al. 2018; Akbari et al. 2014) could be involved in the development of IBD. Similarly, *Enterobac- teriaceae* have been identified as possible markers of micro- biota instability predisposing to the onset of IBD (Chassaing and Darfeuille-Michaud 2011; Rizzatti et al. 2017). In the present study, the exacerbation of the colitis in rats fed with a DON-contaminated diet was also associated with an increase in the number of *Enterobacteriaceae* in the feces. The last half-century has witnessed increased incidence of IBD in Western and developing countries. DON is the most prevalent fungal toxin present in the food chain in Europe and North America (Knutsen et al., 2017). Our results demonstrated that very low doses of DON exacer- bated the onset and the symptoms of colitis. These effects were associated with local colonic inflammation, an increase in *Enterobacteriaceae* and a modulation of both mucosal and systemic immune response.

As IBD are multifactorial disorders, these findings show that food contaminants including mycotoxins can exacerbate these disorders. This observation is even more worrying as the effect is observed at very low doses that do not modify intestinal barrier functions. Epidemiological studies are needed to confirm the role of the environmental exposome and more specifically of mycotoxins as risk factors in IBD or other immune-related or intestinal disorders.



• Fig. 4 Effect of exposure to DON and DOM-1 on the inflammatory immune response in the ileal *lamina propria* (iLP) of animals treated with 5% DSS induced colitis. a Gating strategies for iLP immune cells Th17 cells, regulatory T cells (CD4<sup>+</sup> CD25<sup>+</sup> FoxP3<sup>+</sup> positive cells), helper T cells (CD4<sup>+</sup> CD25<sup>+</sup> T cells) pro-colitogenic and toler- ogenic dendritic cells. Percentage of Th17 (b), T helper (c), Tregs (d), colitogenic DC (f) and tolerogenic DC (g). Ratio of Treg/T helper cells (e). IL-17 (H), IFNγ (i) and IL-10 (j) cytokine production after 72 h of CD3/CD28 T cell stimulation or not. TNFα (k) and IL-1β (l) cytokine production after 18 h of LPS stimulation or not. Data are representative of two batches of experiments. N = 9 animals per group. Mean values ± SEM are represented. \* $p \le 0.05$ , \*\*\*  $p \le 0.01$ , \*\*\*\*  $p \le 0.001$  between groups of animals fed with control or DON or DOM-1 contaminated diet and treated or not with 5% of DSS




Fig. 5 Effect of exposure to DON and DOM-1 on the inflamma- tory immune response in the spleen of animals treated with 5% DSS induced colitis. Percentage of Th17 (a), Treg (b) and T helper (c). Ratio of Treg/T helper cells (d). IL-17 (e), IFN $\gamma$  (f) and IL-10 (g) cytokine production after 72 h of CD3/CD28 T cell stimulation or not. Data are representative of two batches of experiments. N = 9 animals per group. Mean values  $\pm$  SEM are represented. \*  $p \le 0.05$ , \*\*\*  $p \le 0.01$ , \*\*\*\*  $p \le 0.001$  between groups of animals fed with control or DON or DOM-1 contaminated diet and treated or not with 5% of DSS

Acknowledgements We thank G. Schatzmayr and D. Moll from the BIOMIN Research Center in Tulln (Austria) for the DOM-1 product. We are grateful to Dr L. Guzylack-Piriou and T. Gauthier from Toxalim (Toulouse, France) for their scientific input and help with flow cytom- etry experiments and analysis. The authors wish to thank the staff of the team EZOP for animal care. We are grateful to the UPAE (*Unité de Préparation des Aliments Expérimentaux*, UE0300, Jouy-en-Josas, France) for the preparation of the diets. Thank you to M. Gosselin, L. Murate for excellent technical help. This work was supported by grants from the French National Research Agency (projects CaDON 15-CE21-0001 and Genofood 19-CE34).

#### Compliance with ethical standards

**Conflict of interest** The authors declare that they have no conflict of interest.

#### References

- Abron JD, Singh NP, Mishra MK, Price RL, Nagarkatti M, Nagar- katti PS et al (2018) An endogenous aryl hydrocarbon receptor ligand, ITE, induces regulatory T cells and ameliorates experimental colitis. Am J Physiol Gastrointest Liver Physiol 315:G220–G230. https://doi.org/10.1152/ajpgi.00413.2017
- Akbari P, Braber S, Gremmels H, Koelink PJ, Verheijden KAT, Garssen J et al (2014) Deoxynivalenol: a trigger for intesti- nal integrity breakdown. FASEB J 28:2414–2429. https://doi.org/10.1096/fj.13-238717
- Alassane-Kpembi I, Puel O, Pinton P, Cossalter A-M, Chou T-C, Oswald IP (2017) Co-exposure to low doses of the food contaminants deoxynivalenol and nivalenol has a synergistic inflammatory effect on intestinal explants. Arch Toxicol 91:2677–2687. https://doi.org/10.1007/s00204-016-1902-9
- Ananthakrishnan AN, Bernstein CN, Iliopoulos D (2017) Environ- mental triggers in IBD: a review of progress and evidence. Nat Rev Gastroenterol Hepatol 15:39–49. https://doi.org/10.1038/nrgastro.2017.136
- Arnold DL, McGuire PF, Nera EA, Karpinski KF, Bickis MG, Zawidzka ZZ et al (1986) The toxicity of orally administered deoxynivalenol (vomitoxin) in rats and mice. Food Chem Toxi- col 24:935–941. https://doi.org/10.1016/0278-6915(86)90321-2
- Bracarense APFL, Pierron A, Pinton P, Gerez JR, Schatzmayr G, Moll WD, Zhou T, Oswald IP (2020) Reduced toxicity of 3-epideoxynivalenol and de-epoxy-deoxynivalenol through deoxynivalenol bacterial biotransformation: In vivo analysis in piglets. Food Chem Toxicol 140:111241. https://doi.org/10.1016/j. fct.2020.111241
- Breton J, Daniel C, Vignal C, Body-Malapel M, Garat A, Plé C et al (2016) Does oral exposure to cadmium and lead mediate susceptibility to colitis? The dark-and-bright sides of heavy metals in gut ecology. Sci Rep 6:19200. https://doi.org/10.1038/srep19200
- Cano PM, Seeboth J, Meurens F, Cognie J, Abrami R, Oswald IP et al (2013) Deoxynivalenol as a new factor in the persistence of intestinal inflammatory diseases: an emerging hypothesis through possible modulation of Th17-mediated response. PLoS ONE 8:e53647. https://doi.org/10.1371/journal.pone.0053647
- Chassaing B, Darfeuille-Michaud A (2011) The commensal micro- biota and enteropathogens in the pathogenesis of inflammatory bowel diseases. Gastroenterology 140:1720–1728. https://doi.org/10.1053/j.gastro.2011.01.054
- Chassaing B, Koren O, Goodrich JK, Poole AC, Srinivasan S, Ley RE et al (2015) Dietary emulsifiers impact the mouse gut microbiota promoting colitis and metabolic syndrome. Nature 519:92–96. https://doi.org/10.1038/nature14232
- Chassaing B, Wiele TV, De B, De J, Marzorati M, Gewirtz AT (2017) Dietary emulsifiers directly alter human microbiota composition and gene expression ex vivo potentiating intestinal inflammation. Microbiota 4:1414–1427. https://doi.org/10.1136/gutjnl-2016-313099
- Egger B, Bajaj-Elliott M, MacDonald TT, Inglin R, Eysselein VE, Buchler MW (2000) Characterisation of acute murine dextran sodium sulphate colitis: cytokine profile and dose dependency. Digestion 62:240–248. https://doi.org/10.1159/000007822
- García GR, Payros D, Pinton P, Dogi CA, Laffitte J, Neves M, González Pereyra ML, Cavaglieri LR, Oswald IP (2018) Intestinal toxicity of deoxynivalenol is limited by *Lactobacil- lus rhamnosus* RC007 in pig jejunum explants. Arch Toxicol 92:983–993. https://doi.org/10.1007/s00204-017-2083-x
- Kaplan GG, Ng SC (2017) Understanding and preventing the global increase of inflammatory bowel disease. Gastroenterology 152:313–321.e2. https://doi.org/10.1053/j.gastro.2016.10.020
- Knutsen HK, Alexander J, Barreg L, Ceccatelli S, Cottrill B, Dinovi M et al (2017) Risks to human and animal health related to the presence of deoxynivalenol and its acetylated and modi- fied forms in food and feed. Food Feed 15:34–78. https://doi.org/10.2903/j.efsa.2017.4718
- Larsen JC, Hunt J, Perrin I, Ruckenbauer P (2004) Workshop on tri- chothecenes with a focus on DON: summary report. Toxicol Lett 153:1–22. https://doi.org/10.1016/j.toxlet.2004.04.020
- Leppkes M, Becker C, Ivanov II, Hirth S, Wirtz S, Neufert C et al (2009) RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL- 17F. Gastroenterology 136:257–267. https://doi.org/10.1053/j.gastro.2008.10.018
- Lucioli J, Pinton P, Callu P, Laffitte J, Grosjean F, Kolf-Clauw M et al (2013) The food contaminant deoxynivalenol activates the mitogen activated protein kinases in the intestine: Interest of ex vivo models as an alternative to in vivo experiments. Toxicon 66:31–36. https://doi.org/10.1016/j.toxicon.2013.01.024
- Ludwiczek O, Vannier E, Borggraefe I, Kaser A, Siegmund B, Din- arello CA et al (2004) Imbalance between interleukin-1 agonists and antagonists: relationship to severity of inflammatory bowel disease. Clin Exp Immunol 138:323–329. https://doi.org/10.111 1/j.1365-2249.2004.02599.x
- Maresca M, Fantini J (2010) Some food-associated mycotoxins as potential risk factors in humans predisposed to chronic intestinal inflammatory diseases. Toxicon 56:282–294. https://doi.org/10.1016/j.toxicon.2010.04.016
- Matsuno H, Kayama H, Nishimura J, Sekido Y, Osawa H, Barman S et al (2017) CD103+ dendritic cell function is altered in the colons of patients with ulcerative colitis. Inflamm Bowel Dis 23:1524–1534. https://doi.org/10.1097/MIB.000000000001204
- Morrissey RE, Norred WP, Vesonder RF (1985) Subchronic toxicity of vomitoxin in Sprague-Dawley rats. Food Chem Toxicol 23:995–999. https://doi.org/10.1016/0278-6915(85)90250-9
- Ni J, Chen SF, Hollander D (1996) Effects of dextran sulphate sodium on intestinal epithelial cells and intestinal lymphocytes. Gut 39:234–241. https://doi.org/10.1136/gut.39.2.234

- Opipari A, Franchi L (2015) Role of inflammasomes in intestinal inflammation and Crohn's disease. Inflamm Bowel Dis 21:173–181. https://doi.org/10.1097/MIB.0000000000000230
- Payros D, Alassane-Kpembi I, Pierron A, Loiseau N, Pinton P, Oswald IP (2016) Toxicology of deoxynivalenol and its acety- lated and modified forms. Arch Toxicol 90:2931–2957. https://doi.org/10.1007/s00204-016-1826-4
- Payros D, Dobrindt U, Martin P, Secher T, Bracarense APFL, Boury M et al (2017) The food contaminant deoxynivalenol exacerbates the genotoxicity of gut microbiota. MBio 8:e00007–17. https://doi.org/10.1128/mBio.00007-17
- Pestka JJ (2010) Deoxynivalenol: mechanisms of action, human expo- sure, and toxicological relevance. Arch Toxicol 84:663–679. https://doi.org/10.1007/s00204-010-0579-8
- Pierron A, Mimoun S, Murate LS, Loiseau N, Lippi Y, Bracarense A-PFL et al (2016) Microbial biotransformation of DON: molec- ular basis for reduced toxicity. Sci Rep 6:29105. https://doi.org/10.1038/srep29105
- Pierron A, Bracarense APFL, Cossalter AM, Laffitte J, Schwartz HE et al (2018) Deepoxy-deoxynivalenol retains some immune- modulatory properties of the parent molecule deoxynivalenol in piglets. Arch Toxicol 92:3381–3389. https://doi.org/10.1007/s00204-018-2293-x
- Pieters MN, Freijer J, Baars BJ, Fiolet DC, van Klaveren J, Slob W (2002) Risk assessment of deoxynivalenol in food: concentration limits, exposure and effects. Adv Exp Med Biol 504:235–248
- Pinton P, Oswald IP (2014) Effect of deoxynivalenol and other type B trichothecenes on the intestine: a review. Toxins (Basel) 6:1615–1643. https://doi.org/10.3390/toxins6051615
- Pinton P, Tsybulskyy D, Lucioli J, Laffitte J, Callu P, Lyazhri F et al (2012) Toxicity of deoxynivalenol and its acetylated derivatives on the intestine: differential effects on morphology, barrier function, tight junction proteins, and mitogen-activated protein kinases. Toxicol Sci 130:180–190. https://doi.org/10.1093/toxsc i/kfs239
- Raza A, Yousaf W, Giannella R, Shata MT (2012) Th17 cells: inter- actions with predisposing factors in the immunopathogenesis of inflammatory bowel disease. Expert Rev Clin Immunol 8:161–168. https://doi.org/10.1586/eci.11.96
- Reinecker HC, Steffen M, Witthoeft T, Pflueger I, Schreiber S, Mac- Dermott RP et al (1993) Enhanced secretion of tumour necrosis factoralpha, IL-6, and IL-1 beta by isolated lamina propria mon- onuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 94:174–181
- Rizzatti G, Lopetuso LR, Gibiino G, Binda C, Gasbarrini A (2017) Proteobacteria: a common factor in human diseases. Biomed Res Int 2017:935–1507. https://doi.org/10.1155/2017/9351507
- Robert H, Payros D, Pinton P, Théodorou V, Mercier-Bonin M, Oswald IP (2017) Impact of mycotoxins on the intestine: are mucus and microbiota new targets? J Toxicol Environ Heal Part B Crit Rev 20:249–275. https://doi.org/10.1080/10937404.2017.1326071
- Schultz M, Strauch UG, Watzl S, Obermeier F, Dunger N, Grunwald N et al (2004) Preventive effects of Escherichia coli strain nissle 1917 on acute and chronic intestinal inflammation in two different murine models of colitis. Acute Chronic Intestinal 11:372–378. https://doi.org/10.1128/CDLI.11.2.372
- Sprando RL, Collins TF, Black TN, Olejnik N, Rorie JI, Eppley RM et al (2005) Characterization of the effect of deoxynivalenol on selected male reproductive endpoints. Food Chem Toxicol 43:623–635. https://doi.org/10.1016/j.fct.2004.12.017
- Tamaki H, Nakamura H, Nishio A, Nakase H, Ueno S, Uza N et al (2006) Human thioredoxin-1 ameliorates experimental murine colitis in association with suppressed macrophage inhibitory factor production. Gastroenterology 131:1110–1121. https://doi.org/10.1053/j.gastro.2006.08.023
- Turner PC, Rothwell JA, White KL, Gong Y, Cade JE, Wild CP (2008) Urinary deoxynivalenol is correlated with cereal intake in individuals from the United kingdom. Env Heal Perspect 116:21–25. https://doi.org/10.1289/ehp.10663
- Vignal C, Djouina M, Pichavant M, Caboche S, Waxin C, Beury D et al (2018) Chronic ingestion of deoxynivalenol at human dietary levels impairs intestinal homeostasis and gut microbiota in mice. Toxicol, Arch. https://doi.org/10.1007/s00204-018-2228-6
- Vin K, Rivière G, Leconte S, Cravedi JP, Fremy JM, Oswald IP, Roudot AC, Vasseur P, Jean J, Hulin M, Sirot V (2020) Dietary exposure to mycotoxins in the French infant total diet study. Food Chem Toxicol 140:111301. https://doi.org/10.1016/j.fct.2020.111301
- Wang Z, Wu Q, Kuča K, Dohnal V, Tian Z (2014) Deoxynivalenol: signaling pathways and human exposure risk assessment an update. Arch Toxicol 88:1915–1928. https://doi.org/10.1007/s00204-014-1354-z
- Weimers P, Munkholm P (2018) The natural history of IBD: lessons learned. Curr Treat Options Gastroenterol 16:101–111. https://doi.org/10.1007/s11938-018-0173-3
- Wyatt J, Vogelsang H, Hubl W, Waldhoer T, Lochs H (1993) Intesti- nal permeability and the prediction of relapse in Crohn's disease. Lancet (London, England) 341:1437–1439
- Zhang Y-Z, Li Y-Y (2014) Inflammatory bowel disease: Pathogenesis. World J Gastroenterol 20:91–99. https://doi.org/10.3748/wjg.v20. i1.91